Logo image of ALCLS.PA

CELLECTIS (ALCLS.PA) Stock Fundamental Analysis

EPA:ALCLS - Euronext Paris - Matif - FR0010425595 - Common Stock - Currency: EUR

1.256  +0.05 (+4.32%)

Fundamental Rating

3

ALCLS gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 72 industry peers in the Biotechnology industry. The financial health of ALCLS is average, but there are quite some concerns on its profitability. ALCLS is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ALCLS had negative earnings in the past year.
In the past year ALCLS had a positive cash flow from operations.
ALCLS had negative earnings in each of the past 5 years.
In the past 5 years ALCLS always reported negative operating cash flow.
ALCLS.PA Yearly Net Income VS EBIT VS OCF VS FCFALCLS.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -20M -40M -60M -80M -100M

1.2 Ratios

ALCLS's Return On Assets of -22.55% is in line compared to the rest of the industry. ALCLS outperforms 56.94% of its industry peers.
With a Return On Equity value of -61.78%, ALCLS perfoms like the industry average, outperforming 48.61% of the companies in the same industry.
Industry RankSector Rank
ROA -22.55%
ROE -61.78%
ROIC N/A
ROA(3y)-33.58%
ROA(5y)-27.97%
ROE(3y)-86.97%
ROE(5y)-64.54%
ROIC(3y)N/A
ROIC(5y)N/A
ALCLS.PA Yearly ROA, ROE, ROICALCLS.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20 -40 -60 -80 -100

1.3 Margins

ALCLS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALCLS.PA Yearly Profit, Operating, Gross MarginsALCLS.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -200 -400 -600 -800 -1K

More info and screens

4

2. Health

2.1 Basic Checks

ALCLS does not have a ROIC to compare to the WACC, probably because it is not profitable.
ALCLS has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ALCLS has been increased compared to 5 years ago.
ALCLS has a worse debt/assets ratio than last year.
ALCLS.PA Yearly Shares OutstandingALCLS.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M
ALCLS.PA Yearly Total Debt VS Total AssetsALCLS.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

2.2 Solvency

Based on the Altman-Z score of -1.70, we must say that ALCLS is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -1.70, ALCLS perfoms like the industry average, outperforming 44.44% of the companies in the same industry.
ALCLS has a debt to FCF ratio of 2.12. This is a good value and a sign of high solvency as ALCLS would need 2.12 years to pay back of all of its debts.
The Debt to FCF ratio of ALCLS (2.12) is better than 93.06% of its industry peers.
A Debt/Equity ratio of 0.65 indicates that ALCLS is somewhat dependend on debt financing.
ALCLS has a Debt to Equity ratio (0.65) which is in line with its industry peers.
Although ALCLS does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
Industry RankSector Rank
Debt/Equity 0.65
Debt/FCF 2.12
Altman-Z -1.7
ROIC/WACCN/A
WACC6.17%
ALCLS.PA Yearly LT Debt VS Equity VS FCFALCLS.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M 200M 300M 400M

2.3 Liquidity

ALCLS has a Current Ratio of 1.92. This is a normal value and indicates that ALCLS is financially healthy and should not expect problems in meeting its short term obligations.
ALCLS's Current ratio of 1.92 is in line compared to the rest of the industry. ALCLS outperforms 43.06% of its industry peers.
ALCLS has a Quick Ratio of 1.92. This is a normal value and indicates that ALCLS is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.92, ALCLS is in line with its industry, outperforming 47.22% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.92
Quick Ratio 1.92
ALCLS.PA Yearly Current Assets VS Current LiabilitesALCLS.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 32.35% over the past year.
ALCLS shows a strong growth in Revenue. In the last year, the Revenue has grown by 47.81%.
The Revenue for ALCLS have been decreasing by -15.57% on average. This is quite bad
EPS 1Y (TTM)32.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25.81%
Revenue 1Y (TTM)47.81%
Revenue growth 3Y-46.36%
Revenue growth 5Y-15.57%
Sales Q2Q%997.93%

3.2 Future

The Earnings Per Share is expected to grow by 25.75% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 49.22% on average over the next years. This is a very strong growth
EPS Next Y60.81%
EPS Next 2Y20.13%
EPS Next 3Y25.75%
EPS Next 5YN/A
Revenue Next Year169.93%
Revenue Next 2Y73.21%
Revenue Next 3Y15.73%
Revenue Next 5Y49.22%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ALCLS.PA Yearly Revenue VS EstimatesALCLS.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 50M 100M 150M
ALCLS.PA Yearly EPS VS EstimatesALCLS.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 -1 -2 -3 -4

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

ALCLS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ALCLS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALCLS.PA Price Earnings VS Forward Price EarningsALCLS.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, ALCLS is valued cheaper than 98.61% of the companies in the same industry.
Industry RankSector Rank
P/FCF 2.75
EV/EBITDA N/A
ALCLS.PA Per share dataALCLS.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as ALCLS's earnings are expected to grow with 25.75% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.13%
EPS Next 3Y25.75%

More info and screens

0

5. Dividend

5.1 Amount

ALCLS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CELLECTIS

EPA:ALCLS (3/7/2025, 7:00:00 PM)

1.256

+0.05 (+4.32%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04 2024-11-04/amc
Earnings (Next)04-28 2025-04-28/amc
Inst Owners20.91%
Inst Owner ChangeN/A
Ins Owners3.88%
Ins Owner ChangeN/A
Market Cap125.72M
Analysts86.15
Price Target5.1 (306.05%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)64.81%
Min EPS beat(2)6.42%
Max EPS beat(2)123.21%
EPS beat(4)3
Avg EPS beat(4)13.26%
Min EPS beat(4)-95.8%
Max EPS beat(4)123.21%
EPS beat(8)5
Avg EPS beat(8)9.17%
EPS beat(12)8
Avg EPS beat(12)12.57%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)74.43%
Min Revenue beat(2)50.31%
Max Revenue beat(2)98.54%
Revenue beat(4)2
Avg Revenue beat(4)2.07%
Min Revenue beat(4)-76.23%
Max Revenue beat(4)98.54%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)18.83%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)31.47%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.91
P/FCF 2.75
P/OCF 2.65
P/B 0.92
P/tB 0.92
EV/EBITDA N/A
EPS(TTM)-1.04
EYN/A
EPS(NY)-0.91
Fwd EYN/A
FCF(TTM)0.46
FCFY36.37%
OCF(TTM)0.47
OCFY37.72%
SpS0.26
BVpS1.37
TBVpS1.36
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -22.55%
ROE -61.78%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM 178.72%
ROA(3y)-33.58%
ROA(5y)-27.97%
ROE(3y)-86.97%
ROE(5y)-64.54%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.07
Health
Industry RankSector Rank
Debt/Equity 0.65
Debt/FCF 2.12
Debt/EBITDA N/A
Cap/Depr 9.74%
Cap/Sales 6.65%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.92
Quick Ratio 1.92
Altman-Z -1.7
F-Score4
WACC6.17%
ROIC/WACCN/A
Cap/Depr(3y)46.06%
Cap/Depr(5y)230.5%
Cap/Sales(3y)24.1%
Cap/Sales(5y)60.65%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)32.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25.81%
EPS Next Y60.81%
EPS Next 2Y20.13%
EPS Next 3Y25.75%
EPS Next 5YN/A
Revenue 1Y (TTM)47.81%
Revenue growth 3Y-46.36%
Revenue growth 5Y-15.57%
Sales Q2Q%997.93%
Revenue Next Year169.93%
Revenue Next 2Y73.21%
Revenue Next 3Y15.73%
Revenue Next 5Y49.22%
EBIT growth 1Y-5.11%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year41.4%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y141.33%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y146.1%
OCF growth 3YN/A
OCF growth 5YN/A